Philip C Robinson

List of Publications by Year in Descending Order

138 papers	4,534 citations	33 h-index	64 g-index
165 ext. papers	6,386 ext. citations	5.5 avg, IF	6.31 L-index

#	Paper	IF	Citations
138	Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study.. *Lancet Rheumatology, The*, **2022**,	14.2	3
137	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.. *Lancet Rheumatology, The*, **2022**,	14.2	4
136	Dr. Conway et al reply.. *Journal of Rheumatology*, **2022**, 49, 120-121	4.1	
135	The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.. *Rheumatology Advances in Practice*, **2022**, 6, rkac001	1.1	0
134	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.. *Nature Reviews Rheumatology*, **2022**,	8.1	9
133	Waiting for JAK inhibitor safety data.. *RMD Open*, **2022**, 8,	5.9	6
132	COVID-19 therapeutics: Challenges and directions for the future.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2119893119	11.5	9
131	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.. *RMD Open*, **2022**, 8,	5.9	1
130	Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol. *Arthritis Care and Research*, **2021**, 73, 1537-1543	4.7	2
129	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. *JAMA Network Open*, **2021**, 4, e2129639	10.4	17
128	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. *Lancet Rheumatology, The*, **2021**, 3, e855-e864	14.2	11
127	What does endemic COVID-19 mean for the future of rituximab?. *Lancet Rheumatology, The*, **2021**,	14.2	1
126	Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. *Current Opinion in Rheumatology*, **2021**, 33, 111-116	5.3	8
125	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. *Journal of Rheumatology*, **2021**, 48, 1053-1059	4.1	10
124	Divergent effects of acute versus chronic glucocorticoids in COVID-19. *Lancet Rheumatology, The*, **2021**, 3, e168-e170	14.2	15
123	Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. *Best Practice and Research in Clinical Rheumatology*, **2021**, 35, 101657	5.3	13
122	Response to: SCorrespondence on SFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registrySby Mulhearn. *Annals of the Rheumatic Diseases*, **2021**,	2.4	46

121	Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond. *Current Rheumatology Reports*, **2021**, 23, 36	4.9	1
120	Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. *ACR Open Rheumatology*, **2021**, 3, 333-340	3.5	11
119	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. *Annals of the Rheumatic Diseases*, **2021**, 80, 1137-1146	2.4	49
118	Patients with gout: an under-recognised group at high risk of COVID-19. *Lancet Rheumatology, The*, **2021**, 3, e317-e318	14.2	4
117	Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. *Internal Medicine Journal*, **2021**, 51, 788-792	1.6	1
116	Response to: SCorrespondence on SFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registrySby Rosenbaum. *Annals of the Rheumatic Diseases*, **2021**,	2.4	
115	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. *International Journal of Rheumatic Diseases*, **2021**, 24, 733-745	2.3	8
114	COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies. *The Cochrane Library*, **2021**, 2021,	5.2	78
113	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies **2021**, 9,		17
112	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. *Current Opinion in Rheumatology*, **2021**, 33, 412-418	5.3	2
111	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. *Arthritis and Rheumatology*, **2021**, 73, 374-380	9.5	29
110	SARS CoV-2 infection among patients using immunomodulatory therapies. *Annals of the Rheumatic Diseases*, **2021**, 80, 269-271	2.4	20
109	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. *Rheumatology*, **2021**, 60, 353-358	3.9	17
108	Axial spondyloarthritis: concept, construct, classification and implications for therapy. *Nature Reviews Rheumatology*, **2021**, 17, 109-118	8.1	21
107	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. *Lancet Rheumatology, The*, **2021**, 3, e71-e82	14.2	9
106	Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. *Rheumatology Advances in Practice*, **2021**, 5, rkab031	1.1	1
105	Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this?. *Lancet Rheumatology, The*, **2021**, 3, e88-e90	14.2	5
104	Response to: SCorrespondence on SFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registrySby Arnaud and Devilliers. *Annals of the Rheumatic Diseases*, **2021**,	2.4	

103	The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 121-128	5.3	1
102	A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 101-112	5.3	5
101	Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. *BMC Rheumatology*, **2021**, 5, 33	2.9	
100	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. *Annals of the Rheumatic Diseases*, **2021**,	2.4	
99	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. *Annals of the Rheumatic Diseases*, **2021**,	2.4	3
98	Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. *Rheumatology and Therapy*, **2021**, 8, 1603-1616	4.4	
97	The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. *ACR Open Rheumatology*, **2021**, 3, 699-706	3.5	1
96	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. *American Journal of Medicine*, **2021**,	2.4	3
95	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. *Journal of Rheumatology*, **2021**,	4.1	3
94	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. *RMD Open*, **2021**, 7,	5.9	36
93	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. *Lancet Rheumatology, The*, **2021**, 3, e707-e714	14.2	11
92	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Annals of the Rheumatic Diseases*, **2021**, 80, 930-942	2.4	210
91	Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis.. *Rheumatology and Therapy*, **2021**, 9, 1	4.4	0
90	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. *Med*, **2020**, 1, 90-102	32.7	51
89	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. *Expert Review of Clinical Immunology*, **2020**, 16, 1185-1204	5.1	18
88	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Annals of the Rheumatic Diseases*, **2020**, 79, 859-866	2.4	575
87	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. *Annals of the Rheumatic Diseases*, **2020**, 79, 1386-1388	2.4	56
86	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci **2020**, 61, 3		20

85	Glossary of terms for musculoskeletal radiology. *Skeletal Radiology*, **2020**, 49, 1-33	2.7	24
84	Inter- and intra-reader reproducibility of shear wave elastography measurements for musculoskeletal soft tissue masses. *Skeletal Radiology*, **2020**, 49, 779-786	2.7	2
83	The effect of reducing systemic inflammation on serum urate. *Rheumatology*, **2020**, 59, 3108-3109	3.9	2
82	The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. *Nature Reviews Rheumatology*, **2020**, 16, 293-294	8.1	64
81	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. *Expert Review of Clinical Immunology*, **2020**, 16, 659-666	5.1	40
80	Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. *Arthritis Research and Therapy*, **2020**, 22, 28	5.7	57
79	Time to recognise gout as a chronic disease. *Medical Journal of Australia*, **2020**, 212, 285-285.e1	4	1
78	Biologic therapy for uveitis: addressing access issues is paramount. *Internal Medicine Journal*, **2020**, 50, 508-509	1.6	3
77	Conducting research in a pandemic: The power of social media. *European Journal of Rheumatology*, **2020**, 7, S85-S88	1.7	5
76	Non-neoplastic Soft Tissue Tumors and Tumor-like Lesions. *Seminars in Musculoskeletal Radiology*, **2020**, 24, 645-666	1.8	0
75	Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: Comment on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with	2.4	4
74	Adherence to allopurinol in patients with gout: further insights generate further questions. *Lancet Rheumatology, The*, **2020**, 2, e249-e250	14.2	
73	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. *ACR Open Rheumatology*, **2020**, 2, 491-495	3.5	3
72	Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. *Current Opinion in Rheumatology*, **2020**, 32, 434-440	5.3	32
71	Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. *Lancet Rheumatology, The*, **2020**, 2, e653-e655	14.2	85
70	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco . Compassionate use of	2.4	6
69	Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. *Internal Medicine Journal*, **2020**, 50, 337-341	1.6	5
68	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. *Lancet Rheumatology, The*, **2020**, 2, e250-e253	14.2	125

67	Author reply. *Internal Medicine Journal*, **2020**, 50, 387	1.6	
66	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. *Annals of the Rheumatic Diseases*, **2020**, 79, 734-736	2.4	32
65	Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine	2.4	4
64	Response to: Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by Gyftfi. *Annals of the Rheumatic Diseases*, **2020**,	2.4	7
63	Top-Ten Tips for Imaging Groin Injury in Athletes. *Seminars in Musculoskeletal Radiology*, **2019**, 23, 361-375	1.8	3
62	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. *Annals of the Rheumatic Diseases*, **2019**, 78, 1592-1600	2.4	45
61	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. *Rheumatology and Therapy*, **2019**, 6, 165-177	4.4	18
60	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. *Arthritis Care and Research*, **2019**, 71, 427-434	4.7	39
59	Shear-Wave Elastography of Benign versus Malignant Musculoskeletal Soft-Tissue Masses: Comparison with Conventional US and MRI. *Radiology*, **2019**, 290, 410-417	20.5	17
58	SAPHO and CRMO: The Value of Imaging. *Seminars in Musculoskeletal Radiology*, **2018**, 22, 207-224	1.8	33
57	The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. *Journal of Rheumatology*, **2018**, 45, 697-704	4.1	8
56	Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. *Journal of Rheumatology*, **2018**, 45, 771-778	4.1	28
55	Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. *Annals of the Rheumatic Diseases*, **2018**, 77, 1091-1093	2.4	10
54	Febuxostat for the treatment of hyperuricaemia in gout. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 1289-1299	4	14
53	Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. *PeerJ*, **2018**, 6, e5088	3.1	2
52	EVOLVE: The Australian Rheumatology Association's 'top five' list of investigations and interventions doctors and patients should question. *Internal Medicine Journal*, **2018**, 48, 135-143	1.6	8
51	Gout - An update of aetiology, genetics, co-morbidities and management. *Maturitas*, **2018**, 118, 67-73	5	38
50	Imaging of Muscle Injuries in Sports Medicine: Sports Imaging Series. *Radiology*, **2017**, 282, 646-663	20.5	61

49	Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand. *Journal of Medical Imaging and Radiation Oncology*, **2017**, 61, 58-69	1.7	7
48	Lesinurad for the treatment of hyperuricaemia in people with gout. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1875-1881	4	9
47	Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site. *International Journal of Rheumatic Diseases*, **2017**, 20, 779-784	2.3	21
46	MR Imaging of Impingement and Entrapment Syndromes of the Foot and Ankle. *Magnetic Resonance Imaging Clinics of North America*, **2017**, 25, 145-158	1.6	8
45	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. *Clinical and Experimental Rheumatology*, **2017**, 35, 229-233	2.2	16
44	Imaging Athletic Groin Pain. *Radiologic Clinics of North America*, **2016**, 54, 865-73	2.3	12
43	Management of thyroid disease in pregnancy - Room for improvement in the first trimester. *Obstetric Medicine*, **2016**, 9, 126-9	1.5	1
42	The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis. *Genes and Immunity*, **2016**, 17, 46-51	4.4	27
41	Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease. *Npj Genomic Medicine*, **2016**, 1, 16008	6.2	21
40	Insight into rheumatological cause and effect through the use of Mendelian randomization. *Nature Reviews Rheumatology*, **2016**, 12, 486-96	8.1	28
39	The management of gout: Much has changed. *Australian Family Physician*, **2016**, 45, 299-302		5
38	Does midlife obesity really lower dementia risk?. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 501	18.1	2
37	Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis. *Rheumatology*, **2015**, 54, 1549-56	3.9	28
36	ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers. *Annals of the Rheumatic Diseases*, **2015**, 74, 2092-5	2.4	14
35	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. *Annals of the Rheumatic Diseases*, **2015**, 74, 1627-9	2.4	63
34	ERAP1 biology and assessment in Ankylosing Spondylitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1816	11.5	12
33	Role of genetics in infection-associated arthritis. *Best Practice and Research in Clinical Rheumatology* , **2015**, 29, 213-25	5.3	5
32	The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward. *Current Rheumatology Reports*, **2015**, 17, 62	4.9	27

31	The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. *Best Practice and Research in Clinical Rheumatology*, **2015**, 29, 202-12	5.3	26
30	An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. *Journal of Rheumatology*, **2015**, 42, 1702-7	4.1	62
29	Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. *Internal Medicine Journal*, **2015**, 45, 127-33	1.6	5
28	Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. *Arthritis and Rheumatology*, **2015**, 67, 140-51	9.5	78
27	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. *Nature Communications*, **2015**, 6, 7146	17.4	164
26	Do MRI and ultrasound of the anterior pelvis correlate with, or predict, young football playersS clinical findings? A 4-year prospective study of elite academy soccer players. *British Journal of Sports Medicine*, **2015**, 49, 176-82	10.3	25
25	Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. *Genes and Immunity*, **2015**, 16, 35-42	4.4	26
24	Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. *Arthritis and Rheumatology*, **2015**, 67, 686-691	9.5	252
23	Advances in pharmacotherapy for the treatment of gout. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 533-46	4	21
22	The window of opportunity: a relevant concept for axial spondyloarthritis. *Arthritis Research and Therapy*, **2014**, 16, 109	5.7	34
21	Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. *Maturitas*, **2014**, 78, 245-51	5	53
20	Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department. *Microbial Drug Resistance*, **2014**, 20, 561-7	2.9	11
19	Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). *International Journal of Rheumatic Diseases*, **2014**, 17, 548-56	2.3	9
18	Genetics of ankylosing spondylitis. *Molecular Immunology*, **2014**, 57, 2-11	4.3	96
17	Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis. *Current Rheumatology Reports*, **2013**, 15, 317	4.9	26
16	A qualitative and quantitative analysis of the characteristics of gout patient education resources. *Clinical Rheumatology*, **2013**, 32, 771-8	3.9	25
15	Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. *Rheumatology*, **2013**, 52, 118-26	3.9	58
14	Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2013**, 72, 162-4	2.4	59

13	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nature Genetics*, **2013**, 45, 730-8	36.3	551
12	Systematic review of the prevalence of gout and hyperuricaemia in Australia. *Internal Medicine Journal*, **2012**, 42, 997-1007	1.6	69
11	The genetics of ankylosing spondylitis and axial spondyloarthritis. *Rheumatic Disease Clinics of North America*, **2012**, 38, 539-53	2.4	38
10	Conventional 3-T MRI and 1.5-T MR arthrography of femoroacetabular impingement. *American Journal of Roentgenology*, **2012**, 199, 509-15	5.4	34
9	Decreasing time to treatment in rheumatoid arthritis: review of delays in presentation, referral and assessment. *International Journal of Clinical Rheumatology*, **2011**, 6, 173-187	1.5	
8	Rothia aeria as a cause of sepsis in a native joint. *Journal of Clinical Microbiology*, **2010**, 48, 2648-50	9.7	31
7	Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals. *Journal of Clinical Rheumatology*, **2010**, 16, 267-73	1.1	32
6	Sonography of common tendon injuries. *American Journal of Roentgenology*, **2009**, 193, 607-18	5.4	69
5	Impingement syndromes of the ankle. *European Radiology*, **2007**, 17, 3056-65	8	48
4	Venous thromboembolism in medical inpatients--the silent epidemic of neglect. *Journal of the Royal Society of Medicine*, **2005**, 98, 484-5	2.3	2
3	Severe hypothermia in association with sodium valproate overdose. *New Zealand Medical Journal*, **2005**, 118, U1681	0.8	4
2	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry		2
1	Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank		1